HomeCompareSZUKF vs PFE

SZUKF vs PFE: Dividend Comparison 2026

SZUKF yields 1.93% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $18.3K in total portfolio value· pulled ahead in Year 9
10 years
SZUKF
SZUKF
● Live price
1.93%
Share price
$30.30
Annual div
$0.59
5Y div CAGR
24%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.2K
Annual income
$2,432.69
Full SZUKF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SZUKF vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSZUKFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SZUKF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SZUKF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SZUKF
Annual income on $10K today (after 15% tax)
$164.32/yr
After 10yr DRIP, annual income (after tax)
$2,067.79/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $20,252.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SZUKF + PFE for your $10,000?

SZUKF: 50%PFE: 50%
100% PFE50/50100% SZUKF
Portfolio after 10yr
$40.4K
Annual income
$14,345.71/yr
Blended yield
35.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SZUKF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
2.7
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SZUKF buys
0
PFE buys
0
No recent congressional trades found for SZUKF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSZUKFPFE
Forward yield1.93%6.13%
Annual dividend / share$0.59$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR24%13.2%
Portfolio after 10y$31.2K$49.6K
Annual income after 10y$2,432.69$26,258.71
Total dividends collected$9.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: SZUKF vs PFE ($10,000, DRIP)

YearSZUKF PortfolioSZUKF Income/yrPFE PortfolioPFE Income/yrGap
1$10,940$239.72$9,153$693.39+$1.8KSZUKF
2$12,009$303.91$8,593$849.25+$3.4KSZUKF
3$13,237$386.64$8,336$1,066.78+$4.9KSZUKF
4$14,657$493.86$8,437$1,384.80+$6.2KSZUKF
5$16,317$633.73$9,013$1,875.40+$7.3KSZUKF
6$18,277$817.58$10,306$2,680.72+$8.0KSZUKF
7$20,617$1,061.28$12,820$4,101.38+$7.8KSZUKF
8$23,448$1,387.40$17,673$6,826.70+$5.8KSZUKF
9← crossover$26,918$1,828.58$27,543$12,591.86$625.00PFE
10$31,235$2,432.69$49,560$26,258.71$18.3KPFE

SZUKF vs PFE: Complete Analysis 2026

SZUKFStock

Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the wholesale of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution Business, Pharmaceutical Manufacturing Business, Pharmacy Business, and Healthcare-Related Services Business. The Pharmaceutical Distribution Business segment procures ethical drugs, diagnostic reagents, medical equipment and supplies, and other health-related items from manufacturers and supplies to medical institutions and pharmacies. The Pharmaceutical Manufacturing Business segment engages in the research and development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products focusing on the areas of diabetes and kidney diseases. The Pharmacy Business segment provides services through family pharmacists, as well as improves the operations of local pharmacies and provides educational support. The Healthcare-Related Services Business segment provides manufacturer support services, such as contract distribution for manufacturers; distribution of orphan drugs; and nursing care services, as well as develops, manufactures, and sells electrocardiographs, sphygmomanometers, stethoscopes, medical materials, and health promotion equipment. Suzuken Co., Ltd. also publishes medical magazines for medical institutions. The company has collaboration with Bushu Pharmaceuticals Ltd. provide contract specialty drug services. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.

Full SZUKF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SZUKF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SZUKF vs SCHDSZUKF vs JEPISZUKF vs OSZUKF vs KOSZUKF vs MAINSZUKF vs JNJSZUKF vs MRKSZUKF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.